Biocon won US FDA approval for Pebrilzo, its biosimilar to Roche's breast cancer drug Perjeta.
Legal · 16 Nov 2026 · Biocon (BIOCON)
It is Biocon's fifth US oncology biosimilar. Its Genentech settlement sets the earliest US launch in 2028.
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.